Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATYR aTyr Pharma	$5.35 +8.1%	$5.30	$1.67 ▼ $7.29	$524.23M	0.94	4.96 million shs	6.03 million shs
IKT Inhibikase Therapeutics	$1.89 +12.5%	$1.77	$1.12 ▼ $4.20	$125.19M	0.9	191,826 shs	218,894 shs
MBX MBX Biosciences	$14.33 +1.3%	$12.51	$4.81 ▼ $27.50	$481.40M	N/A	328,877 shs	280,074 shs
SLDB Solid Biosciences	$5.93 +4.8%	$5.74	$2.41 ▼ $10.07	$461.76M	2.44	1.16 million shs	794,407 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATYR aTyr Pharma	0.00%	+9.18%	-3.60%	+42.67%	+184.57%
IKT Inhibikase Therapeutics	0.00%	+8.00%	+2.16%	+6.78%	+30.34%
MBX MBX Biosciences	0.00%	-2.65%	+9.98%	+17.94%	+1,432,999,900.00%
SLDB Solid Biosciences	0.00%	-2.95%	-11.23%	+111.03%	-40.40%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATYR aTyr Pharma	2.525 of 5 stars	3.6	1.0	3.3	1.7	0.6
IKT Inhibikase Therapeutics	1.4084 of 5 stars	3.3	2.0	1.1	0.0	0.6
MBX MBX Biosciences	1.9512 of 5 stars	3.5	0.0	1.1	1.7	0.6
SLDB Solid Biosciences	3.4075 of 5 stars	4.6	2.0	2.7	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATYR aTyr Pharma	3.17	Buy	$23.25	334.58% Upside
IKT Inhibikase Therapeutics	2.50	Moderate Buy	$6.50	243.92% Upside
MBX MBX Biosciences	3.00	Buy	$37.63	162.56% Upside
SLDB Solid Biosciences	3.17	Buy	$15.00	152.95% Upside

Current Analyst Ratings Breakdown

Latest IKT, MBX, ATYR, and SLDB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/22/2025	ATYR aTyr Pharma	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$9.00 ➝ $17.00
8/14/2025	SLDB Solid Biosciences	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00
8/14/2025	SLDB Solid Biosciences	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$15.00 ➝ $13.00
8/13/2025	SLDB Solid Biosciences	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$17.00 ➝ $14.00
8/5/2025	MBX MBX Biosciences	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$38.00
7/21/2025	SLDB Solid Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Overweight ➝ Overweight	$16.00
7/16/2025	MBX MBX Biosciences	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$38.00
6/26/2025	SLDB Solid Biosciences	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$14.00
6/26/2025	SLDB Solid Biosciences	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$14.00
6/20/2025	ATYR aTyr Pharma	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$17.00 ➝ $25.00
6/17/2025	SLDB Solid Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00

(Data available from 8/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATYR aTyr Pharma	$230K	2,279.33	N/A	N/A	$0.76 per share	7.04
IKT Inhibikase Therapeutics	N/A	N/A	N/A	N/A	$1.78 per share	N/A
MBX MBX Biosciences	N/A	N/A	N/A	N/A	N/A	N/A
SLDB Solid Biosciences	$8.09M	57.08	N/A	N/A	$3.32 per share	1.79

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATYR aTyr Pharma	-$64.02M	-$0.80	N/A	N/A	N/A	N/A	-93.69%	-68.83%	11/6/2025 (Estimated)
IKT Inhibikase Therapeutics	-$19.03M	-$2.67	N/A	N/A	N/A	N/A	-350.63%	-201.82%	N/A
MBX MBX Biosciences	N/A	-$4.54	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SLDB Solid Biosciences	-$124.70M	-$2.80	N/A	N/A	N/A	N/A	-69.70%	-56.74%	11/5/2025 (Estimated)

Latest IKT, MBX, ATYR, and SLDB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/12/2025	Q2 2025	SLDB Solid Biosciences	-$0.51	-$0.42	+$0.09	-$0.42	N/A	N/A
8/7/2025	Q2 2025	ATYR aTyr Pharma	-$0.18	-$0.22	-$0.04	-$0.22	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATYR aTyr Pharma	N/A	N/A	N/A	N/A	N/A
IKT Inhibikase Therapeutics	N/A	N/A	N/A	N/A	N/A
MBX MBX Biosciences	N/A	N/A	N/A	N/A	N/A
SLDB Solid Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATYR aTyr Pharma	0.01	5.63	5.63
IKT Inhibikase Therapeutics	N/A	0.85	0.85
MBX MBX Biosciences	N/A	N/A	N/A
SLDB Solid Biosciences	N/A	9.34	9.34

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATYR aTyr Pharma	61.72%
IKT Inhibikase Therapeutics	3.81%
MBX MBX Biosciences	N/A
SLDB Solid Biosciences	81.46%

Insider Ownership

Company	Insider Ownership
ATYR aTyr Pharma	3.70%
IKT Inhibikase Therapeutics	7.30%
MBX MBX Biosciences	52.19%
SLDB Solid Biosciences	1.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATYR aTyr Pharma	53	97.99 million	94.36 million	Optionable
IKT Inhibikase Therapeutics	6	74.52 million	66.18 million	Not Optionable
MBX MBX Biosciences	36	33.59 million	N/A	N/A
SLDB Solid Biosciences	100	77.87 million	76.39 million	Optionable

IKT, MBX, ATYR, and SLDB Headlines

Recent News About These Companies

Monashee Investment Management LLC Grows Position in Solid Biosciences Inc. $SLDB

August 23 at 8:31 AM | marketbeat.com

Leerink Partnrs Issues Optimistic Forecast for SLDB Earnings

August 19, 2025 | marketbeat.com

Q3 EPS Forecast for Solid Biosciences Increased by Analyst

August 19, 2025 | americanbankingnews.com